Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $1.9 million.

  • Denali Therapeutics' Change in Accured Expenses fell 9231.68% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$975000.0, marking a year-over-year decrease of 10477.87%. This contributed to the annual value of $17.4 million for FY2024, which is 55623.11% up from last year.
  • Latest data reveals that Denali Therapeutics reported Change in Accured Expenses of $1.9 million as of Q3 2025, which was down 9231.68% from -$7.7 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Change in Accured Expenses registered a high of $24.6 million during Q3 2024, and its lowest value of -$32.2 million during Q2 2023.
  • Its 5-year average for Change in Accured Expenses is $1.2 million, with a median of $2.3 million in 2024.
  • In the last 5 years, Denali Therapeutics' Change in Accured Expenses tumbled by 64917.31% in 2023 and then skyrocketed by 324959.13% in 2024.
  • Quarter analysis of 5 years shows Denali Therapeutics' Change in Accured Expenses stood at $7.8 million in 2021, then crashed by 48.16% to $4.0 million in 2022, then soared by 255.43% to $14.3 million in 2023, then fell by 21.14% to $11.3 million in 2024, then tumbled by 83.26% to $1.9 million in 2025.
  • Its Change in Accured Expenses stands at $1.9 million for Q3 2025, versus -$7.7 million for Q2 2025 and -$6.5 million for Q1 2025.